Marketdash
Back to Stock Market News

Big Wednesday Winners: Monte Rosa Soars 45% on Clinical Data, Ventyx Jumps on Eli Lilly Acquisition Talks

MarketDash Editorial Team
1 day ago
Wednesday's trading session delivered some dramatic movers despite mixed market conditions. Monte Rosa Therapeutics surged 45% on promising Phase 1 clinical data, while Ventyx Biosciences jumped 37% amid reports of a potential $1 billion-plus acquisition by Eli Lilly. Here's a look at the day's biggest gainers.

The Dow Jones slipped about 0.2% on Wednesday, but plenty of individual stocks had a very different kind of day. Biotechs, semiconductors, and a few wild cards delivered some eye-popping gains that made for an interesting session if you knew where to look.

The Headliners: Biotech Makes Moves

Monte Rosa Therapeutics Inc. (GLUE) absolutely dominated the day's action, rocketing 45.2% to $23.25. The catalyst? Interim data from an ongoing Phase 1 clinical study evaluating MRT-8102 that apparently got investors extremely excited about what they're seeing so far.

Not far behind was Ventyx Biosciences Inc. (VTYX), which surged 37.5% to $13.82. According to The Wall Street Journal, Indianapolis-based Eli Lilly & Co. (LLY) is in advanced talks to acquire the company for more than $1 billion. That's the kind of headline that tends to wake up a stock price in a hurry.

Neumora Therapeutics Inc. (NMRA) joined the biotech party with a 24.7% climb to $2.27, though no specific catalyst was immediately apparent.

Analyst Upgrades and Strong Fundamentals

Erasca Inc. (ERAS) rose 17.1% to $4.25 after catching the attention of Wall Street. Piper Sandler analyst Kelsey Goodwin initiated coverage on Erasca with an Overweight rating and announced a price target of $5, giving the stock some fresh momentum.

Over in the semiconductor space, United Microelectronics Corp. (UMC) gained 10.4% to $8.96 after the company reported December and full-year sales growth. When chip manufacturers show solid revenue expansion, investors notice.

Intel Corp. (INTC) gained 6.4% to $42.60 on news that the company is ramping up its gaming ambitions by developing a new chip and platform specifically for handheld gaming devices. Intel trying something new in gaming might not sound revolutionary, but the market liked the strategic direction.

The Rest of the Gainers

Several other names posted impressive gains throughout the session. Regencell Bioscience Holdings Ltd. (RGC) gained 21.1% to $40.00, while Anywhere Real Estate Inc. (HOUS) climbed 15.6% to $16.71.

AXT Inc. (AXTI) rose 13.8% to $22.96, and Immuneering Corp. (IMRX) gained 13.1% to $7.60. Compass Therapeutics Inc. (CMPX) also gained 13.1% to $5.56, continuing the strong day for biotech names.

MBX Biosciences Inc. (MBX) rose 11.2% to $31.90, while Rezolve AI PLC (RZLV) climbed 10.8% to $3.36. PBF Energy Inc. (PBF) rose 9.2% to $29.73, showing that energy stocks weren't sitting out the gains entirely.

Navan Inc. (NAVN) rose 8.3% to $18.42, matching the percentage gain of Ascentage Pharma Group International (AAPG), which climbed 8.3% to $28.17. Ascentage Pharma announced IND clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288, giving the stock a regulatory catalyst to work with.

While the broader market treaded water, these individual names showed that specific catalysts, acquisition rumors, and positive clinical data still have the power to drive serious single-session gains.

Back to Stock Market News

Big Wednesday Winners: Monte Rosa Soars 45% on Clinical Data, Ventyx Jumps on Eli Lilly Acquisition Talks

MarketDash Editorial Team
1 day ago
Wednesday's trading session delivered some dramatic movers despite mixed market conditions. Monte Rosa Therapeutics surged 45% on promising Phase 1 clinical data, while Ventyx Biosciences jumped 37% amid reports of a potential $1 billion-plus acquisition by Eli Lilly. Here's a look at the day's biggest gainers.

The Dow Jones slipped about 0.2% on Wednesday, but plenty of individual stocks had a very different kind of day. Biotechs, semiconductors, and a few wild cards delivered some eye-popping gains that made for an interesting session if you knew where to look.

The Headliners: Biotech Makes Moves

Monte Rosa Therapeutics Inc. (GLUE) absolutely dominated the day's action, rocketing 45.2% to $23.25. The catalyst? Interim data from an ongoing Phase 1 clinical study evaluating MRT-8102 that apparently got investors extremely excited about what they're seeing so far.

Not far behind was Ventyx Biosciences Inc. (VTYX), which surged 37.5% to $13.82. According to The Wall Street Journal, Indianapolis-based Eli Lilly & Co. (LLY) is in advanced talks to acquire the company for more than $1 billion. That's the kind of headline that tends to wake up a stock price in a hurry.

Neumora Therapeutics Inc. (NMRA) joined the biotech party with a 24.7% climb to $2.27, though no specific catalyst was immediately apparent.

Analyst Upgrades and Strong Fundamentals

Erasca Inc. (ERAS) rose 17.1% to $4.25 after catching the attention of Wall Street. Piper Sandler analyst Kelsey Goodwin initiated coverage on Erasca with an Overweight rating and announced a price target of $5, giving the stock some fresh momentum.

Over in the semiconductor space, United Microelectronics Corp. (UMC) gained 10.4% to $8.96 after the company reported December and full-year sales growth. When chip manufacturers show solid revenue expansion, investors notice.

Intel Corp. (INTC) gained 6.4% to $42.60 on news that the company is ramping up its gaming ambitions by developing a new chip and platform specifically for handheld gaming devices. Intel trying something new in gaming might not sound revolutionary, but the market liked the strategic direction.

The Rest of the Gainers

Several other names posted impressive gains throughout the session. Regencell Bioscience Holdings Ltd. (RGC) gained 21.1% to $40.00, while Anywhere Real Estate Inc. (HOUS) climbed 15.6% to $16.71.

AXT Inc. (AXTI) rose 13.8% to $22.96, and Immuneering Corp. (IMRX) gained 13.1% to $7.60. Compass Therapeutics Inc. (CMPX) also gained 13.1% to $5.56, continuing the strong day for biotech names.

MBX Biosciences Inc. (MBX) rose 11.2% to $31.90, while Rezolve AI PLC (RZLV) climbed 10.8% to $3.36. PBF Energy Inc. (PBF) rose 9.2% to $29.73, showing that energy stocks weren't sitting out the gains entirely.

Navan Inc. (NAVN) rose 8.3% to $18.42, matching the percentage gain of Ascentage Pharma Group International (AAPG), which climbed 8.3% to $28.17. Ascentage Pharma announced IND clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288, giving the stock a regulatory catalyst to work with.

While the broader market treaded water, these individual names showed that specific catalysts, acquisition rumors, and positive clinical data still have the power to drive serious single-session gains.